Controversies in osteoporosis management

Antiresorptive therapy for preventing bone loss: When to use one or two antiresorptive agents?

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.

Original languageEnglish
Pages (from-to)749-756
Number of pages8
JournalClinical Obstetrics and Gynecology
Volume56
Issue number4
DOIs
StatePublished - Dec 2013

Fingerprint

Bone Density Conservation Agents
Osteoporosis
Diphosphonates
Bone and Bones
Bone Density
Calcium
Selective Estrogen Receptor Modulators
Calcitriol
Osteoclasts
Therapeutics
Hormones

All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this

@article{78a4cb95c09b421d925bf112698885b6,
title = "Controversies in osteoporosis management: Antiresorptive therapy for preventing bone loss: When to use one or two antiresorptive agents?",
abstract = "Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.",
author = "Gallagher, {John Christopher G.} and Tella, {Sri Harsha}",
year = "2013",
month = "12",
doi = "10.1097/GRF.0b013e3182a982c2",
language = "English",
volume = "56",
pages = "749--756",
journal = "Clinical Obstetrics and Gynecology",
issn = "0009-9201",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Controversies in osteoporosis management

T2 - Antiresorptive therapy for preventing bone loss: When to use one or two antiresorptive agents?

AU - Gallagher, John Christopher G.

AU - Tella, Sri Harsha

PY - 2013/12

Y1 - 2013/12

N2 - Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.

AB - Women who have significant bone loss or a new fracture on monotherapy are considered for combination therapy. Combination therapies increase bone density more than monotherapy by targeting different parts of the osteoclast pathway.In early postmenopausal women who are symptomatic, the use of combination antiresorptives should include hormone therapy with a bisphosphonate or with bazodoxifene. In women who initially receive a weaker antiresorptive such as the SERM raloxifene, a combination with bisphosphonates and calcium supplementation is necessary to prevent bone loss. In older women over 65 years of age who often have impaired calcium absorption, the combination of calcitriol with bisphosphonates has been shown to increase bone density more than monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84887823989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887823989&partnerID=8YFLogxK

U2 - 10.1097/GRF.0b013e3182a982c2

DO - 10.1097/GRF.0b013e3182a982c2

M3 - Article

VL - 56

SP - 749

EP - 756

JO - Clinical Obstetrics and Gynecology

JF - Clinical Obstetrics and Gynecology

SN - 0009-9201

IS - 4

ER -